Trial
NCT06068400
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
UnknownTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Guangzhou Bio-gene Technology Co., Ltd
Collaborators
Shenzhen Nanshan District Shekou People's Hospital
Condition
Relapsed or Refractory Multiple Myeloma
Intervention
BCMA/GPRC5D dual CAR-T
Why stopped
Due to corporate strategic adjustment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-17